Portfolio company
RQ Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
RQ Bio develops long-acting monoclonal antibodies to provide seasonal influenza protection for vulnerable and immunocompromised patients who cannot rely on vaccination alone.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
CoVBio
The company develops broad-spectrum vaccines and therapeutic antibodies to protect the global population against coronaviruses and other respiratory viral infections.
Invivyd
Invivyd develops monoclonal antibody therapies to protect immunocompromised patients from serious viral infectious diseases, including COVID-19 and measles.
Windward Bio
The company develops long-acting monoclonal antibodies for patients with serious respiratory and dermatological diseases, including severe asthma, chronic obstructive pulmonary disease and atopic dermatitis.
Red Queen Bio
This company develops AI-powered antibody drugs and medical countermeasures against biological threats for governments, biopharma organisations and frontier artificial intelligence laboratories.
Upstream Bio
The company develops monoclonal antibody therapies for patients with chronic inflammatory and respiratory diseases, including asthma and chronic rhinosinusitis.
Adagio Therapeutics
This biopharmaceutical company develops monoclonal antibody therapies for the prevention and treatment of viral respiratory diseases, primarily serving immunocompromised patients.
Aqualung
Aqualung Therapeutics develops immunotherapeutic monoclonal antibodies for patients suffering from inflammatory lung injuries and life-threatening fibrosis.
Aerium Therapeutics
This biopharmaceutical company develops monoclonal antibodies and antiviral treatments to protect immunocompromised patients against COVID-19 and future epidemic threats.